logoAardexPng.png

History

  • 1987

    Foundation of APREX and generation 1 & 2 of the MEMS

  • 1989

    First MEMS-based peer-reviewed publication in JAMA

  • 1990

    Generation 3 of the MEMS

  • 1993

    First phase IV clinical study sponsored by Pfizer comparing anti-hypertensive treatments forgiveness.

  • 1994

    Generation 4 of the MEMS

  • 1998

    First audit by a large pharma company (Ely Lilly)

  • 1999

    Foundation of AARDEX in Switzerland and acquisition of APREX

  • 2001

    Generation 5 of the MEMS

  • 2002

    First ISO9001 certification

  • 2003

    Opening of the AARDEX research centre in Belgium

  • 2004

    First FDA filing of MEMS data from a large scale Phase II/III drug development program in HIV

  • 2005

    Generation 6 of the MEMS

  • 2005

    Launch of medAmigo

  • 2007

    Building of the largest repository of dosing history data and the AARDEX knowledge centre

  • 2010

    First deployment of MEMS and medAmigo in large scale drug development of new, all oral, HCV therapies (multi-company, multi-study, multi-country, multi-site).

  • 2012

    Aquisition of AARDEX by MWV

  • 2014

    First large scale adherence-enhancing program based on MEMS and medAmigo in resource-limited setting sponsored by the Bill & Melinda Gates Foundation.

  • 2015

    MWV merger with Rocktenn to become Westrock

  • 2017

    Generation 8 of the MEMS family of smart packages

  • 2018

    MBO from WestRock

  • 2018

    HQ AARDEX Group operating from Belgium with subsidiary AARDEX Group Switzerland

See all